Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been given an average rating of “Moderate Buy” by the nine analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $13.40.

Several research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Argus raised Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st.

Haleon Price Performance

Shares of HLN opened at $9.30 on Tuesday. The company has a market cap of $41.30 billion, a P/E ratio of 23.86, a PEG ratio of 2.12 and a beta of 0.15. The stock has a fifty day moving average price of $9.63 and a 200 day moving average price of $9.97. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon has a 12 month low of $8.71 and a 12 month high of $11.42.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion for the quarter. On average, research analysts forecast that Haleon will post 0.56 earnings per share for the current year.

Haleon Announces Dividend

The firm also recently declared a dividend, which was paid on Thursday, May 14th. Stockholders of record on Friday, April 10th were paid a $0.1307 dividend. The ex-dividend date of this dividend was Friday, April 10th. This represents a dividend yield of 266.0%. Haleon’s dividend payout ratio is presently 64.10%.

Institutional Trading of Haleon

Institutional investors have recently modified their holdings of the company. Western Wealth Management LLC acquired a new stake in shares of Haleon in the first quarter valued at $29,000. Parkside Financial Bank & Trust lifted its stake in Haleon by 101.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares in the last quarter. Atlantic Union Bankshares Corp increased its position in Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Stance Capital LLC acquired a new position in Haleon in the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.